DOCSLIB.ORG

Human Herpesvirus 6 in Cerebrospinal Fluid of Patients Infected with HIV

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Human Herpesvirus 6 in Cerebrospinal Fluid of Patients Infected with HIV J Neurol Neurosurg Psychiatry 1999;67:789–792 789 J Neurol Neurosurg Psychiatry: first published as 10.1136/jnnp.67.6.789 on 1 December 1999. Downloaded from SHORT REPORT Human herpesvirus 6 in cerebrospinal fluid of patients infected with HIV: frequency and clinical significance Simona Bossolasco, Roberta Marenzi, Helena Dahl, Luca Vago, Maria Rosa Terreni, Francesco Broccolo, Adriano Lazzarin, Annika Linde, Paola Cinque Abstract convulsions or other neurological symptoms The objective was to evaluate the fre- complicating exanthema subitum.2–4 HHV-6 quency of human herpesvirus 6 (HHV-6) encephalitis or milder neurological symptoms DNA detection in the CSF of patients have been described in both immunocompet- infected with HIV and its relation to brain ent adults and transplanted patients,5–7 and the disease and systemic HHV-6 infection. virus might also play an aetiological part in Nested polymerase chain reaction multiple sclerosis.8 HHV-6 has also been found (PCR) was used to analyse CSF samples in the brain or CSF of adults and children with from 365 consecutive HIV infected pa- AIDS, but its role in neurological disease is still tients with neurological symptoms. When unclear.9–12 available, plasma and brain tissues from To study the possible relation between patients whose CSF was HHV-6 positive HHV-6 and brain disease in patients infected were also studied. with HIV, the presence of HHV-6-DNA in the HHV-6 was found in the CSF of eight of CSF was assessed in a large group of patients copyright. Division of Infectious the 365 patients (2.2%): two had type A with neurological disease and was correlated Diseases, San RaVaele and four type B; the HHV-6 variant could with clinical and neuropathology patterns. Hospital, Via Stamira not be defined in the remaining two. All d’Ancona 20, 20127 eight patients had neurological symptoms Milano, Italy S Bossolasco and signs related to concomitant oppor- Patients and methods R Marenzi tunistic brain diseases, including cytome- The CSF of 365 consecutive patients infected F Broccolo galovirus (CMV) encephalitis in five with HIV admitted to San RaVaele Hospital in A Lazzarin patients whose CSF was also positive for P Cinque the period 1992–6, was prospectively examined CMV-DNA. Opportunistic infections but for the presence of HHV-6-DNA by polymer- no other unexplained lesions were also Pathology Unit, San ase chain reaction (PCR). All patients included RaVaele Hospital, Via found in the brain of all of the four in the study had CNS symptoms or signs at a http://jnnp.bmj.com/ Olgettina 60, 20132 patients who underwent neuropathologi- physical examination and no contraindications Milano, Italy cal examination. Both HHV-6 and CMV for undergoing a lumbar puncture. Clinical M R Terreni were also detected in the plasma of neurological, neuroradiological, and CSF ex- respectively five and seven of seven amination, also including DNA-PCR for the Pathology Unit, Luigi patients whose CSF was HHV-6 positive. Sacco Hospital, Via identification of herpes simplex virus type 1 GB Grassi 74, 20157 In conclusion, HHV-6 type A or B DNA and 2 (HSV-1, HSV-2), Varicella zoster virus Milano, Italy was infrequently found in the CSF of HIV (VZV), cytomegalovirus (CMV), Epstein-Barr L Vago infected patients, in association with both virus (EBV), and JC virus (JCV)11 were done at on September 24, 2021 by guest. Protected CMV brain infection and systemic HHV-6 the onset of clinical manifestations. The CSF Department of replication. However, no certain relation Virology, Swedish findings relating to 286 of these patients have between HHV-6 and brain disease was 11 Institute for Infectious been presented previously. In patients whose Disease Control and found. CSF was positive for HHV-6-DNA, all of the Microbiology and (J Neurol Neurosurg Psychiatry 1999;67:789–792) available CSF and plasma samples drawn at or Tumor Biology Center, Keywords: HIV infection; human herpesvirus type 6; after the onset of neurological manifestations, Karolinska Institute, ° 17177 Stockholm, cerebrospinal fluid; cytomegalovirus and kept stored at -80 C, were retrospectively Sweden examined. HHV-6 PCR was also applied to H Dahl CSF and plasma samples taken from 20 A Linde Human herpesvirus 6 (HHV-6), variants A neurologically asymptomatic HIV seronegative and B, is a ubiquitous lymphotropic virus. controls (patients who had undergone spinal Correspondence to: Dr Paola Cinque email HHV-6 B is known to be the causative agent anaesthesia) and to plasma samples drawn [email protected] of exanthema subitum, but both variants have from 22 HIV infected patients with other CNS been found in immunocompromised patients.1 diseases whose CSF was HHV-6-DNA nega- Received 10 March 1999 and Clinical evidence supports a role for HHV-6 tive. In all patients the CSF samples were in revised form 25 June 1999 in causing significant CNS disease. The virus is drawn for diagnostic purposes and all of the Accepted 22 July 1999 often found in the CSF of children with febrile patients and controls gave their informed con- 790 Bossolasco, Marenzi, Dahl, et al J Neurol Neurosurg Psychiatry: first published as 10.1136/jnnp.67.6.789 on 1 December 1999. Downloaded from M 12345678910 423 bp 195 bp 176 bp Agarose gel electrophoresis of amplification products after nested PCR for HHV-6 DNA using the standard assay, which amplifies a 173 bp DNA fragment (lanes 1–5) or the subtype PCR assay, which amplifies a 195 bp DNA fragment for group A and a 423 bp DNA fragment for group B (lanes 6–10). M=100 bp DNA ladder marker; lanes 1, 6=HHV-6 variant A positive CSF (patient 1 of the table); lanes 2, 7=HHV-6 variant B positive CSF (patient 2 of the table); lanes 3, 8=DNA-free control; lanes 4, 9=HHV-6 variant A positive control (GS strain); lanes 5, 10=HHV-6 variant B positive control (Z29 strain). sent for the CSF sampling in an approved blindly with respect to the patients’ history in manner. the 365 prospectively examined patients. A nested PCR for HHV-6-DNA detection Postmortem CNS examinations were per- was carried out as previously described.6 The formed in three patients (time interval between positive samples were also tested by another the CSF sampling and necropsy was 1–90 PCR assay which gives products of diVerent days), and brain biopsy in one. The postmor- sizes for the HHV-6 A and B variants, allowing tem examinations involved eight standard copyright. their diVerentiation (“subtype” PCR, figure).13 tissue sections and sections from any other The analytical sensitivity was estimated to be macroscopically visible lesion.11 Tissues were 20 and 50 HHV-6 genomes for the standard fixed in formalin, embedded in paraYn, and and the subtype PCR, respectively.6 Pre-PCR examined after haematoxylin and eosin stain- treatment of CSF and plasma specimens and ing. Special stainings and immunochemical visualisation of amplified products was done as techniques were used for the diagnosis of described.11 PCR examinations were done opportunistic diseases and HIV encephalitis, as PCR, clinical, and histopathological findings in HIV infected patients whose CSF was positive for HHV-6 DNA DNA PCR findings http://jnnp.bmj.com/ CSF HHV-6 CSF Plasma HHV-6 Plasma Antiherpes treatment CNS HHV-6 Patient Sample (days)* (variant) CMV (variant) CMV (days) CNS disease (diagnostic procedure) DNA PCR 1 a (−210) NA NA + (A) + Ganciclovir CMV meningoencephalomyeloradiculitis − b 0 + (A) + NA NA (from−170 to+30) HIV encephalopathy c (+5) + (A) + + (A) + (clinical+necropsy) d (+14) + (A) + NA NA e (+30) + (A) + − + 2 a 0 + (ND) + + (B) + Ganciclovir Toxoplasmosis, CMV encephalitis‡ + (ND)§ b (+12) + (ND) − + (B) + (from+40 to+55) (clinical+necropsy) on September 24, 2021 by guest. Protected c (+28) + (B) + − + d (+55) + (B) − − + 3 a 0 + (B) − − − None Toxoplasmosis NA b (+182) + (B) − NA NA (clinical) c (+421) + (B) − + (B) + 4 a† 0 + (B) + + (B) + Ganciclovir CMV meningoencephalitis NA b (+5) NA NA + (B) + (from−2 to+18) (clinical) c (+24) + (B) − NA − 5 a 0 + (A) − + (A) + Ganciclovir Toxoplasmosis NA (from−50 to−10) (clinical) 6 a (−98) − − NA NA None Toxoplasmosis (clinical+necropsy) − b 0 + (B) − NA NA PML (necropsy) 7 a 0 + (ND) + − + Ganciclovir CMV encephalitis NA b (+100) − + − + (from−180 to+80) (clinical) 8 a† 0 + (ND) + − + None Primary lymphoma (biopsy) − CMV encephalitis (clinical) NA=sample not available; ND=HHV-6 variant not defined; +=positive, −=negative. *In parentheses: number of days before (−) or after (+) CSF sampling in concomitance to onset of neurological disease (0). †Varicella zoster virus (patient 4) or Epstein-Barr virus (patient 8) was also found in the CSF. ‡CMV was demonstrated in the same periventricular areas that were found to be HHV6 positive by PCR. §HHV-6 DNA was found in 5 of 13 sections, including cerebral cortex, basal ganglia, and periventricular areas; no additional material was available for examination by the subtype PCR. Human herpesvirus 6 in cerebrospinal fluid of HIV infected patients 791 J Neurol Neurosurg Psychiatry: first published as 10.1136/jnnp.67.6.789 on 1 December 1999. Downloaded from described.11 Brain tissue samples from the portion of controls, suggesting that diVerent patients whose CSF was HHV-6-DNA positive detection rates may depend on the diVerent were also examined by HHV-6 PCR.11 sensitivity limits of the PCR assays, and that passenger HHV-6 positive blood lymphocytes Results may be detected in CSF if a very sensitive assay HHV-6-DNA was found in the CSF of eight of is used. DiVerently from children with primary the 365 patients (2.2%, table). HHV-6 A was infection and patients with multiple sclerosis, found in two patients and HHV-6 B in four; in in whom the variant B of HHV-6 is predomi- the remaining two patients the HHV-6 variant nantly identified,18both variants were found in was not defined, because the subtype PCR our patient group.
Load more

Recommended publications
  • Impact of Human Cytomegalovirus and Human Herpesvirus 6 Infection
    International Journal of Molecular Sciences Article Impact of Human Cytomegalovirus and Human Herpesvirus 6 Infection on the Expression of Factors Associated with Cell Fibrosis and Apoptosis: Clues for Implication in Systemic Sclerosis Development Maria-Cristina Arcangeletti 1,*, Maria D’Accolti 2 , Clara Maccari 1, Irene Soffritti 2 , Flora De Conto 1, Carlo Chezzi 1, Adriana Calderaro 1, Clodoveo Ferri 3 and Elisabetta Caselli 2 1 Department of Medicine and Surgery, Unit of Virology, University-Hospital of Parma, University of Parma, 43126 Parma, Italy; [email protected] (C.M.); fl[email protected] (F.D.C.); [email protected] (C.C.); [email protected] (A.C.) 2 Department of Chemical and Pharmaceutical Sciences, Section of Microbiology and Medical Genetics, University of Ferrara, 44121 Ferrara, Italy; [email protected] (M.D.); irene.soff[email protected] (I.S.); [email protected] (E.C.) 3 Department of Medical and Surgical Sciences for Children and Adults, Rheumatology Unit, University-Hospital Policlinico of Modena, University of Modena and Reggio Emilia, 41121 Modena, Italy; [email protected] * Correspondence: [email protected]; Tel.: +39-0521-033497 Received: 29 July 2020; Accepted: 31 August 2020; Published: 3 September 2020 Abstract: Systemic sclerosis (SSc) is a severe autoimmune disorder characterized by vasculopathy and multi-organ fibrosis; its etiology and pathogenesis are still largely unknown. Herpesvirus infections, particularly by human cytomegalovirus (HCMV) and human herpesvirus 6 (HHV-6), have been suggested among triggers of the disease based on virological and immunological observations. However, the direct impact of HCMV and/or HHV-6 infection on cell fibrosis and apoptosis at the cell microenvironment level has not yet been clarified.
    [Show full text]
  • But Significantly Different From, Human Herpesvirus 6 and Human Cytomegalovirus (Chronic Fatigue Syndrome/T Lymphocytes) Zwi N
    Proc. Natd. Acad. Sci. USA Vol. 89, pp. 10552-10556, November 1992 Medical Sciences Human herpesvirus 7 is a T-lymphotropic virus and is related to, but significantly different from, human herpesvirus 6 and human cytomegalovirus (chronic fatigue syndrome/T lymphocytes) Zwi N. BERNEMAN*, DHARAM V. ABLASHIt, GE LI*, MAUREEN EGER-FLETCHER*, MARVIN S. REITZ, JR.*, CHIA-LING HUNGO§, IRENA BRUS¶, ANTHONY L. KOMAROFFII, AND ROBERT C. GALLO*,** *Laboratory of Tumor Cell Biology and tLaboratory of Cellular and Molecular Biology, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892; TPharmacia, Columbia, MD 21045; NMount Sinai School of Medicine, New York, NY 10029; and IlDepartment of Internal Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115 Communicated by Maurice Hilleman, August 6, 1992 ABSTRACT An independent strain (JI) of human herpes- for 1-2 hr at 370C with virus-containing culture supernatant. virus 7 (HV-7) was isolated from a patient with chronic Afterward, the cell lines were cultured in RPMI 1640 medi- fatigue syndrome (CFS). No s cant association could be um/2-10%o fetal calf serum, whereas the CBMC were grown established by seroepidemiology between HHV-7 and CFS. in RPMI 1640 medium/5-20%o fetal calf serum with or with- HHV-7 is a T-lymphotropic virus, infecting CD4+ and CD8+ out 10% (vol/vol) interleukin 2 (Advanced Biotechnologies, primary lymphocytes. HHV-7 can also infect SUP-T1, an Columbia, MD). Infection was assessed by the appearance of immature T-cell line, with variable success. Southern blot large cells, immunofluorescence, and EM.
    [Show full text]
  • Clinical Impact of Primary Infection with Roseoloviruses
    Available online at www.sciencedirect.com ScienceDirect Clinical impact of primary infection with roseoloviruses 1 2 1 Brenda L Tesini , Leon G Epstein and Mary T Caserta The roseoloviruses, human herpesvirus-6A -6B and -7 (HHV- infection in different cell types, have the ability to reac- 6A, HHV-6B and HHV-7) cause acute infection, establish tivate, and may be intermittently shed in bodily fluids [3]. latency, and in the case of HHV-6A and HHV-6B, whole virus Unlike other human herpesviruses, HHV-6A and HHV- can integrate into the host chromosome. Primary infection with 6B are also found integrated into the host genome HHV-6B occurs in nearly all children and was first linked to the (ciHHV-6). Integration has been documented in 0.2– clinical syndrome roseola infantum. However, roseolovirus 1% of the general population and along with latency infection results in a spectrum of clinical disease, ranging from has confounded the ability to correlate the presence of asymptomatic infection to acute febrile illnesses with severe viral nucleic acid with active disease [4]. neurologic complications and accounts for a significant portion of healthcare utilization by young children. Recent advances The syndrome known as roseola infantum was reported as have underscored the association of HHV-6B and HHV-7 early as 1809 by Robert Willan in his textbook ‘On primary infection with febrile status epilepticus as well as the cutaneous diseases’ [5]. This clinical entity is also com- role of reactivation of latent infection in encephalitis following monly referred to as exanthem subitum and early pub- cord blood stem cell transplantation.
    [Show full text]
  • Cytomegalovirus, Human Herpesvirus 6, and Bacteriophage T4 DNA Polymerases (Antibody/Viral Enzyme) CHING-HWA ANN TSAI*, MARSHALL V
    Proc. Nati. Acad. Sci. USA Vol. 87, pp. 7963-7%7, October 1990 Medical Sciences A monoclonal antibody that neutralizes Epstein-Barr virus, human cytomegalovirus, human herpesvirus 6, and bacteriophage T4 DNA polymerases (antibody/viral enzyme) CHING-HWA ANN TSAI*, MARSHALL V. WILLIAMS*t, AND RONALD GLASER*tt *Department of Medical Microbiology and Immunology, and tComprehensive Cancer Center, The Ohio State University Medical Center, Columbus, OH 43210 Communicated by Leo A. Paquette, July 23, 1990 (received for review May 18, 1990) ABSTRACT A monoclonal antibody (mAb) designated DNA polymerase activity (20), it is not known whether this 55H3 was produced by using chemically induced Epstein-Barr polyclonal antibody neutralizes the DNA polymerase activity virus genome-positive B95-8 cells. mAb 55H3, which reacted by binding to the enzyme or due to its binding to one of the with an 85- to 80-kDa polypeptide, neutralized Epstein-Barr associated polypeptides. Thus, further studies on the inter- virus-encoded DNA polymerase activity in crude extracts of actions of these polypeptides have been hampered, in part, chemically induced M-ABA, HR-1, and B95-8 cells, as well as from the lack of specific antibodies against the EBV-encoded the partially purified Epstein-Barr virus DNA polymerase in a DNA polymerase. dose-dependent manner. The mAb also neutralized the virus- Recently, we reported the isolation of an EBV-specific encoded DNA polymerase activity from cells infected with monoclonal antibody (mAb), designated 55H3, that neutral- human cytomegalovirus, human herpesvirus 6, and the puri- izes the activity of EBV-encoded DNA polymerase (21). In fied bacteriophage T4 DNA polymerases.
    [Show full text]
  • The Development of New Therapies for Human Herpesvirus 6
    Available online at www.sciencedirect.com ScienceDirect The development of new therapies for human herpesvirus 6 2 1 Mark N Prichard and Richard J Whitley Human herpesvirus 6 (HHV-6) infections are typically mild and data from viruses are generally analyzed together and in rare cases can result in encephalitis. A common theme reported simply as HHV-6 infections. Here, we will among all the herpesviruses, however, is the reactivation upon specify the specific virus where possible and will simply immune suppression. HHV-6 commonly reactivates in use the HHV-6 designation where it is not. Primary transplant recipients. No therapies are approved currently for infection with HHV-6B has been shown to be the cause the treatment of these infections, although small studies and of exanthem subitum (roseola) in infants [4], and can also individual case reports have reported intermittent success with result in an infectious mononucleosis-like illness in adults drugs such as cidofovir, ganciclovir, and foscarnet. In addition [5]. Infections caused by HHV-6A and HHV-7 have not to the current experimental therapies, many other compounds been well characterized and are typically reported in the have been reported to inhibit HHV-6 in cell culture with varying transplant setting [6,7]. Serologic studies indicated that degrees of efficacy. Recent advances in the development of most people become infected with HHV-6 by the age of new small molecule inhibitors of HHV-6 will be reviewed with two, most likely through saliva transmission [8]. The regard to their efficacy and spectrum of antiviral activity. The receptors for HHV-6A and HHV-6B have been identified potential for new therapies for HHV-6 infections will also be as CD46 and CD134, respectively [9,10].
    [Show full text]
  • Human Herpesvirus-6 and -7 in the Brain Microenvironment of Persons with Neurological Pathology and Healthy People
    International Journal of Molecular Sciences Article Human Herpesvirus-6 and -7 in the Brain Microenvironment of Persons with Neurological Pathology and Healthy People Sandra Skuja 1,* , Simons Svirskis 2 and Modra Murovska 2 1 Institute of Anatomy and Anthropology, R¯ıga Stradin, š University, Kronvalda blvd 9, LV-1010 R¯ıga, Latvia 2 Institute of Microbiology and Virology, R¯ıga Stradin, š University, Ratsup¯ ¯ıtes str. 5, LV-1067 R¯ıga, Latvia; [email protected] (S.S.); [email protected] (M.M.) * Correspondence: [email protected]; Tel.: +371-673-20421 Abstract: During persistent human beta-herpesvirus (HHV) infection, clinical manifestations may not appear. However, the lifelong influence of HHV is often associated with pathological changes in the central nervous system. Herein, we evaluated possible associations between immunoexpression of HHV-6, -7, and cellular immune response across different brain regions. The study aimed to explore HHV-6, -7 infection within the cortical lobes in cases of unspecified encephalopathy (UEP) and nonpathological conditions. We confirmed the presence of viral DNA by nPCR and viral antigens by immunohistochemistry. Overall, we have shown a significant increase (p < 0.001) of HHV antigen expression, especially HHV-7 in the temporal gray matter. Although HHV-infected neurons were found notably in the case of HHV-7, our observations suggest that higher (p < 0.001) cell tropism is associated with glial and endothelial cells in both UEP group and controls. HHV-6, predominantly detected in oligodendrocytes (p < 0.001), and HHV-7, predominantly detected in both astrocytes and oligodendrocytes (p < 0.001), exhibit varying effects on neural homeostasis.
    [Show full text]
  • Persistent Infection with Human Herpesvirus-6 in Patients with an Inherited Form of the Virus
    University of South Florida Scholar Commons Graduate Theses and Dissertations Graduate School January 2013 Persistent Infection with Human Herpesvirus-6 in Patients with an Inherited Form of the Virus: A Newly Described Disease Shara Pantry University of South Florida, [email protected] Follow this and additional works at: http://scholarcommons.usf.edu/etd Part of the Virology Commons Scholar Commons Citation Pantry, Shara, "Persistent Infection with Human Herpesvirus-6 in Patients with an Inherited Form of the Virus: A Newly Described Disease" (2013). Graduate Theses and Dissertations. http://scholarcommons.usf.edu/etd/4928 This Dissertation is brought to you for free and open access by the Graduate School at Scholar Commons. It has been accepted for inclusion in Graduate Theses and Dissertations by an authorized administrator of Scholar Commons. For more information, please contact [email protected]. Persistent Human Herpesvirus-6 Infection in Patients with an Inherited Form of the Virus: a Newly Described Disease by Shara N. Pantry A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy Department of Molecular Medicine College of Medicine University of South Florida Major Professor: Peter G. Medveczky, M.D. George Blanck, Ph.D. Gloria Ferreira, Ph.D. Ed Seto, Ph.D. Date of Approval November 5, 2013 Keywords: HHV-6, Chronic Fatigue Syndrome, Inherited Herpesvirus Syndrome, Virus Integration, Telomere Copyright © 2013, Shara N. Pantry DEDICATION I dedicate this dissertation to my grandparents, Ladric and Retinella Lewis, my parents, Beverley and Everard Pantry, and to my brothers, Marlondale and Lamonte Pantry. I would also like to dedicate this dissertation, to my niece and nephew, Chaniah and Marlondale Pantry.
    [Show full text]
  • Herpesviral Latency—Common Themes
    pathogens Review Herpesviral Latency—Common Themes Magdalena Weidner-Glunde * , Ewa Kruminis-Kaszkiel and Mamata Savanagouder Department of Reproductive Immunology and Pathology, Institute of Animal Reproduction and Food Research of Polish Academy of Sciences, Tuwima Str. 10, 10-748 Olsztyn, Poland; [email protected] (E.K.-K.); [email protected] (M.S.) * Correspondence: [email protected] Received: 22 January 2020; Accepted: 14 February 2020; Published: 15 February 2020 Abstract: Latency establishment is the hallmark feature of herpesviruses, a group of viruses, of which nine are known to infect humans. They have co-evolved alongside their hosts, and mastered manipulation of cellular pathways and tweaking various processes to their advantage. As a result, they are very well adapted to persistence. The members of the three subfamilies belonging to the family Herpesviridae differ with regard to cell tropism, target cells for the latent reservoir, and characteristics of the infection. The mechanisms governing the latent state also seem quite different. Our knowledge about latency is most complete for the gammaherpesviruses due to previously missing adequate latency models for the alpha and beta-herpesviruses. Nevertheless, with advances in cell biology and the availability of appropriate cell-culture and animal models, the common features of the latency in the different subfamilies began to emerge. Three criteria have been set forth to define latency and differentiate it from persistent or abortive infection: 1) persistence of the viral genome, 2) limited viral gene expression with no viral particle production, and 3) the ability to reactivate to a lytic cycle. This review discusses these criteria for each of the subfamilies and highlights the common strategies adopted by herpesviruses to establish latency.
    [Show full text]
  • Human Herpesvirus-6 Infections
    98 Dollery 22 Kirkpatrick CJ. Microcirculatory problems in multiple organ failure: the role 29 Levy M, Benson LN, Burrows PE, et al. Tissue plasminogen activator for of endotoxins and particulate contamination. In: Lee HA, Barnet MI, eds. the treatment ofthromboembolism in infants and children. JPediatr 1991; Proceedings of the symposium on managing the complications of intravenous 118: 467-72. Arch Dis Child: first published as 10.1136/adc.74.2.98 on 1 February 1996. Downloaded from therapy. Portsmouth: Pall Biomedical, 1993: 5-13. 30 Rodenhuis S, van't Hek LGFM, Vlasveld T, Kroger R, Dubbelman R, van 23 Bamett MI, Coslett AG, Cohen J. Filtration of lipid containing total par- Tol RGL. Central venous catheter associated thrombosis of major veins: enteral nutrition (TPN) admixtures [Abstract]. Clinical Nutrition 1995; 14 thrombolytic treatment with recombinant tissue plasminogen activator. (suppl 2): 49. Thorax 1993; 48: 558-9. 24 Andrew M, Marzinotto V, Massicotte P, et al. Heparin therapy in pediatric 31 Farfel Z, Shechter M, Vered Z, et al. Review of echocardiographically diag- patients: a prospective cohort study. Pediatr Res 1994; 35: 78-83. nosed right heart entrapment ofpulmonary emboli-in-transit with empha- 25 Hirsh J, van Aken WG, Gallus AS, Dollery CT, Cade JF, Yung WL. sis on management. Am HeartJ 1986; 113: 171-8. Heparin kinetics in venous thrombosis and pulmonary embolism. 32 Cameron J, Pohner PG, Stafford EG, et al. Right heart thrombus: recogni- Circulation 1976; 53: 691-5. tion, diagnosis, and management. J Am Coll Cardiol 1985; 5: 1239-43. 26 Owens JP, Mirtallo JM, Murphy CC.
    [Show full text]
  • Current in Vivo Models of Varicella-Zoster Virus Neurotropism
    viruses Review Current In Vivo Models of Varicella-Zoster Virus Neurotropism Ravi Mahalingam 1,* , Anne Gershon 2 , Michael Gershon 3, Jeffrey I. Cohen 4, Ann Arvin 5, Leigh Zerboni 5, Hua Zhu 6 , Wayne Gray 7, Ilhem Messaoudi 8 and Vicki Traina-Dorge 9 1 Department of Neurology, University of Colorado School of Medicine, Anschutz Medical Campus, Aurora, CO 80045, USA 2 Department of Pediatrics, Columbia University College of Physicians and Surgeons, New York, NY 10032, USA; [email protected] 3 Department of Microbiology, Columbia University College of Physicians and Surgeons, New York, NY 10032, USA; [email protected] 4 Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA; [email protected] 5 Pediatric Infectious Disease, Stanford University, Stanford, CA 94305, USA; [email protected] (A.A.); [email protected] (L.Z.) 6 Department of Microbiology, Biochemistry and Molecular Genetics, New Jersey Medical School, Rutgers University, Newark, NJ 07102, USA; [email protected] 7 Biology Department, University of Mississippi, Oxford, MS 38677, USA; [email protected] 8 Departments of Molecular Biology and Biochemistry, School of Biological Sciences, University of California Irvine, Irvine, CA 92697, USA; [email protected] 9 Division of Microbiology, Tulane University, Tulane National Primate Research Center, Covington, LA 70433, USA; [email protected] * Correspondence: [email protected]; Tel.: +1-303-724-4324 Received: 1 February 2019; Accepted: 28 May 2019; Published: 31 May 2019 Abstract: Varicella-zoster virus (VZV), an exclusively human herpesvirus, causes chickenpox and establishes a latent infection in ganglia, reactivating decades later to produce zoster and associated neurological complications.
    [Show full text]
  • Management of Varicella Zoster Virus (Vzv) Infections
    MANAGEMENT OF VARICELLA ZOSTER VIRUS (VZV) INFECTIONS Federal Bureau of Prisons Clinical Guidance DECEMBER 2016 Federal Bureau of Prisons (BOP) Clinical Guidance is made available to the public for informational purposes only. The BOP does not warrant this guidance for any other purpose, and assumes no responsibility for any injury or damage resulting from the reliance thereof. Proper medical practice necessitates that all cases are evaluated on an individual basis and that treatment decisions are patient- specific. Consult the BOP Health Management Resources Web page to determine the date of the most recent update to this document: http://www.bop.gov/resources/health_care_mngmt.jsp Federal Bureau of Prisons Management of VZV Infections Clinical Guidance December 2016 WHAT’S NEW IN THIS DOCUMENT? What is new in the December 2016 version of this document? • Duplication of information is minimized. • Varicella IgM testing is not recommended for either suspected varicella cases or contacts, because of low sensitivity and specificity (see Appendix 1, Varicella Testing). • Procedures for contact investigation have been simplified and clarified (see Appendix 3, Varicella Contact Investigation Checklist). • VariZIG for post-exposure prophylaxis is now commercially available. What was new in the December 2011 version of this document? • A digital Varicella Timeline Calculator (for determining the exposure and infectious periods of an index case and the incubation period of exposed contacts) was added to the BOP website (http://www.bop.gov/resources/health_care_mngmt.jsp). • Treatment of post-herpetic neuralgia associated with herpes zoster was clarified (see Treatment of Herpes Zoster/Shingles in Section 6, Treatment). • It was emphasized that inmates with herpes zoster (shingles) should be housed in a single cell if the secretions from the lesions cannot be easily contained (see Housing Inmates with Varicella or Herpes Zoster in Section 7, Control Measures).
    [Show full text]
  • Varicella-Zoster Virus ORF9 Is an Antagonist of the DNA Sensor Cgas ABSTRACT
    bioRxiv preprint doi: https://doi.org/10.1101/2020.02.11.943415; this version posted February 11, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. 1 Varicella-Zoster Virus ORF9 Is an Antagonist of the DNA Sensor 2 cGAS 3 4 Jonny Hertzog1, Rachel E. Rigby1, Sonja Roll1, Chiara Cursi1, Lise Chauveau1, Tamara 5 Davenne1, and Jan Rehwinkel1,* 6 7 1MRC Human Immunology Unit, MRC Weatherall Institute of Molecular Medicine, 8 Radcliffe Department of Medicine, University of Oxford, Oxford, UK 9 10 *correspondence: [email protected] 11 12 13 ABSTRACT 14 15 Varicella-Zoster virus (VZV) causes chickenpox and shingles. Although infection is 16 associated with severe morbidity in some individuals, the molecular mechanisms that 17 determine innate immune responses remain poorly defined. We found that the 18 cGAS/STING DNA sensing pathway was critically required for type I interferon (IFN) 19 induction in response to VZV infection. Viral gene overexpression screening identified 20 the essential VZV tegument protein ORF9 as a novel antagonist of DNA sensing via 21 cGAS. Ectopically as well as virally expressed ORF9 bound to endogenous cGAS. 22 Confocal microscopy revealed co-localisation of cGAS and ORF9, which blocked the 23 type I IFN response to transfected DNA. ORF9 and cGAS also interacted directly in a 24 cell-free system. Our data further suggest that ORF9 inhibited the production of 25 cGAMP by cGAS.
    [Show full text]